15-hydroxyprostaglandin dehydrogenase [NAD(+)]

BE0000552ProteinHumansHPGD

Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed:10837478, PubMed:16757471, PubMed:16828555, PubMed:21916491, PubMed:25586183, PubMed:8086429). It is acted on by 6 drugs in DrugBank.

Gene name
HPGD
UniProtKB entry
P15428Swiss-Prot
Cellular location
Cytoplasm
Residues / weight
266 residues · 28,977 Da
Also known as
1.1.1.141 · 15-PGDH · Eicosanoid/docosanoid dehydrogenase [NAD(+)] · PGDH1 · Prostaglandin dehydrogenase 1

Resolves to

Protein
UniProtP15428UniProt namePGDH_HUMAN
Gene
HGNCHGNC:5154NCBI Gene3248GenBank1203984GeneCardsHPGD
Pharmacology
IUPHAR/GtoPdb1384KEGGhsa:3248
Structure
PDB2GDZPDB8CVNPDB8CWL
Drugs

What you can answer from here — as of September 07, 2019

6DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
1Clinical trialTrials of drugs acting on it, by phase and status
Sign in
1Metabolic reactionDrug transformations it catalyses, substrate to product
Sign in
13GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
39+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on 15-hydroxyprostaglandin dehydrogenase [NAD(+)], how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In